





Acute Seizure treatment when IV access is not available • Diazepam Rectal Gel (marketed) • Intranasal diazepam (under development) • Intranasal midazolam (under development) • Buccal midazolam maleate (Epistatus) and midazolam HCI (Buccolam) • oromucosal solution









Clinical Applications

 Prevent seizure spread in aura (selfadministration)



Acute repetitive seizures (facemask by caregiver bystander)




Propofol Antizeizure Activity


- Profound antiseizure activity in diverse animal seizure models, including status epilepticus
- Commonly used clinically in refractory status epilepticus
- Powerful anticonvulsant: confers seizure protection at low (nonanesthetic) -large therapeutic window provides antiseizure efficacy with no or minimal side effects
- Rapid onset
- Short duration, so that period of sedation, if any, does not interfere with patient's daily activities

Seizure Protection by Intrapulmonary Delivery of Propofol Hemisuccinate

Ashish Dhir, Dorota Zolkowska, Randall B. Murphy, and Michael A. Rogawski Department of Neurology, School of Medicine (A.D. D.Z., MAR) and Center for Neuroscience (MAR), University of California-Davis, Sectemento, California and Medicus Pharmacouticals, Fairfeid, New Jensey (R.B.M) Beroward server 3 Strict Investered Neuroscience 3 2015

Michael A. Rogawski, M.D., Ph.D.





Propofol Problems

- Irritating, weak acid (pKa of 11), small amount in anionic form, causes pain on i.v. injection
- Liquid, insoluble in water


No pharmaceutically suitable salts




Propofol


 Neither pure propofol nor i.v. formulation (soybean oil emulsion) can be safelyadministered into lung


Non-specific Esterase in Lung Mammalian lung is rich in non-specific esterase activity High esterase activity in bronchial mucosa and to a lesser extent in the alveolar lining cells (alveolar septal cells and type II alveocytes)





Convulsant agent	PHS dose (mg/kg) for threshold elevation of myoclonic jerks, clonic seizure and tonic extension		
	i.v.	i.p.	Intratracheal
PTZ	40	60	10
		i.p.	Intratracheal
Bicuculline	60		15
Picrotoxin	60		5-10
Kainate	Not tested		10
NMDA	Not effective		Not effective
4-aminopyridine	Not tested		10











GMP Manufacturing of API, Formulation, IND-Enabling Studies

- NINDS National Center for Advancing TranslationalScience (NCATS) is assisting with support of pre-clinical development to enable clinical trials
- BrIDGs Grant Award 1 X01 NS074960
- Activities
 - > Chemistry, Manufacturing and Control
 - > Pharmacology
 - Toxicology

NINDS/ BrIDGs Progress

- Preparation of GMP PHS-COMPLETED
- Novel lyophilized formulation (additional patent protection) COMPLETED
- Manufacture of a sterile lyophilized dosage form -COMPLETED
- Bioanalytical method -COMPLETED
- 2 years stability studies of clinical batch IN PROGRESS
- In vitro genotoxicity BEGIN SHORTLY
- GLP inhalation and systemic toxicology BEGIN SHORTLY